Prise en charge de l'hépatite C chronique en 2012 en Belgique [Management of chronic hepatitis C in 2012 in Belgium].

Details

Serval ID
serval:BIB_3806942AA304
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Title
Prise en charge de l'hépatite C chronique en 2012 en Belgique [Management of chronic hepatitis C in 2012 in Belgium].
Journal
Revue Médicale de Bruxelles
Author(s)
Moreno C., Deltenre P.
ISSN
0035-3639 (Print)
ISSN-L
0035-3639
Publication state
Published
Issued date
2012
Volume
33
Number
4
Pages
223-227
Language
french
Notes
Publication types: English Abstract ; Journal Article ; ReviewPublication Status: ppublish
Abstract
Chronic hepatitis C virus infection is a major public health problem. It is estimated that 15 to 35% of infected patients will develop cirrhosis after a period of 30 years. Fibrosis stage must be evaluated in all hepatitis-C-infected patients. Noninvasive methods for the evaluation of liver fibrosis have been developed, mainly serum markers and transient elastography or Fibroscan. The goal of therapy is to achieve a sustained virological response, defined by hepatitis C RNA undetectable in serum 6 months after the end of therapy. This indicates viral eradication. Treatment of chronic hepatitis C has considerably improved. The association of pegylated interferon with ribavirin remains the standard of care for non-genotype-1-infected patients. Genotype-1-infected patients (who represent the majority of cases) are preferentially treated by triple therapy pegylated interferon plus ribavirin plus a first generation protease inhibitor (telaprevir or boceprevir). While triple therapy represents a major advance, by increasing the possibility of viral eradication, such therapy also presents new challenges, including the need for strict compliance, risk of additional side effects and development of resistant variants, drug-drug interactions, etc., which call for first-rate expertise in management of chronic hepatitis C therapy. Several new antiviral compounds are currently in clinical development and might lead to viral eradication in the vast majority of infected patients in the near future.
Keywords
Antiviral Agents/adverse effects, Antiviral Agents/therapeutic use, Belgium/epidemiology, Drug Combinations, Drug Interactions, Hepatitis C, Chronic/epidemiology, Hepatitis C, Chronic/therapy, Humans, Models, Biological, Oligopeptides/administration & dosage, Oligopeptides/adverse effects, Proline/administration & dosage, Proline/adverse effects
Pubmed
Create date
06/12/2013 10:04
Last modification date
20/08/2019 13:26
Usage data